| Citation: |
CHANG Jinyi, WANG Wei, CAI Haifeng. Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 965-969. DOI: 10.3971/j.issn.1000-8578.2022.21.1462
|
HER2 gene is expressed in 20%-30% of breast cancer patients, and HER2 expression provides a new direction for treatment. However, breast cancer with positive HER2 still has a poor prognosis and is prone to recurrence and metastasis. Trastuzumab is a classic basic drug for anti-HER2 therapy. However, the problem of primary and acquired drug resistance of trastuzumab has attracted people's attention. Studies have found that the occurrence of insensitive and drug resistance mechanism is related to PD-L1 up-regulation on tumor cell surface. Therefore, a large number of studies on PD-1/PD-L1 inhibitor combined with trastuzumab were carried out to improve its sensitivity and drug resistance. This article reviews the preclinical and clinical studies on PD-1/PD-L1 inhibitors in breast cancer with positive HER2.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Sun Y, Li W, Li AJ, et al. Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patients[J]. Cancer Manag Res, 2019, 11: 3153-3162. doi: 10.2147/CMAR.S190335
|
| [2] |
Piccart MJ, Hilbers FS, Bliss JM, et al. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors[J]. J Clin Oncol, 2020, 38(34): 4120-4129. doi: 10.1200/JCO.20.01382
|
| [3] |
Griguolo G, Pascual T, Dieci MV, et al. Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer[J]. J Immunother Cancer, 2019, 7(1): 90. doi: 10.1186/s40425-019-0548-6
|
| [4] |
Adams S, Gatti-Mays ME, Kalinsky K, et al. Current Landscape of Immunotherapy in Breast Cancer: A Review[J]. JAMA Oncol, 2019, 5(8): 1205-1214. doi: 10.1001/jamaoncol.2018.7147
|
| [5] |
Chaganty BKR, Qiu S, Gest A, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion[J]. Cancer Lett, 2018, 430: 47-56. doi: 10.1016/j.canlet.2018.05.009
|
| [6] |
Zheng G, Guo Z, Li W, et al. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab[J]. Signal Transduct Target Ther, 2021, 6(1): 236. doi: 10.1038/s41392-021-00629-w
|
| [7] |
Nakayama Y, Mimura K, Tamaki T, et al. Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer[J]. Int J Oncol, 2019, 54(6): 2030-2038.
|
| [8] |
Yamashita K, Iwatsuki M, Yasuda-oshihara N, et al. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer[J]. Br J Cancer, 2021, 124(3): 595-603. doi: 10.1038/s41416-020-01138-3
|
| [9] |
Mittal D, Vijayan D, Neijssen J, et al. Blockade of ErbB2 and PD- L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy[J]. Oncoimmunology, 2019, 8(11): e1648171. doi: 10.1080/2162402X.2019.1648171
|
| [10] |
Chen YL, Cui Y, Liu X, et al. A Bispecific Antibody Targeting HER2 and PD-L1 Inhibits Tumor Growth with Superior Efficacy[J]. J Biol Chem, 2021, 297(6): 101420. doi: 10.1016/j.jbc.2021.101420
|
| [11] |
Gu CL, Zhu HX, Deng L, et al. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition[J]. Acta Pharmacol Sin, 2022, 43(3): 672-680. doi: 10.1038/s41401-021-00683-8
|
| [12] |
Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(6): 732-742. doi: 10.1016/S1470-2045(17)30312-1
|
| [13] |
No authors listed. Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate[J]. Cancer Discov, 2016, 6(2): OF3. doi: 10.1158/2159-8290.CD-NB2015-172
|
| [14] |
Müller P, Kreuzaler M, Khan T, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade[J]. Sci Transl Med, 2015, 7(315): 315ra188.
|
| [15] |
Early Breast Cancer Trialists' Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13864 women in seven randomised trials[J]. Lancet Oncol, 2021, 22(8): 1139-1150. doi: 10.1016/S1470-2045(21)00288-6
|
| [16] |
Swain SM, Baselga J, Kim SB, et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer[J]. N Engl J Med, 2015, 372(8): 724-734. doi: 10.1056/NEJMoa1413513
|
| [17] |
Fabi A, Malaguti P, Vari S, et al. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?[J]. J Exp Clin Cancer Res, 2016, 35: 104. doi: 10.1186/s13046-016-0380-5
|
| [18] |
Lambertini M, Pondé NF, Solinas C, et al. Adjuvant trastuzumab: a 10-year overview of its benefit[J]. Expert Rev Anticancer Ther, 2017, 17(1): 61-74. doi: 10.1080/14737140.2017.1264876
|
| [19] |
Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial[J]. Lancet Oncol, 2019, 20(3): 371-382. doi: 10.1016/S1470-2045(18)30812-X
|
| [20] |
Chia S, Bedard PL, Hilton J, et al. A PhaseⅠb Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND. 229)[J]. Oncologist, 2019, 24(11): 1439-1445. doi: 10.1634/theoncologist.2019-0321
|
| [21] |
Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial[J]. Lancet Oncol, 2020, 21(10): 1283-1295. doi: 10.1016/S1470-2045(20)30465-4
|
| [22] |
Hamilton EP, Kaklamani V, Falkson C, et al. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a PhaseⅠb Study[J]. Clin Breast Cancer, 2021, 21(6): 539-551. doi: 10.1016/j.clbc.2021.04.011
|
| [23] |
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50. doi: 10.1016/S1470-2045(17)30904-X
|
| [24] |
Solinas C, Fumagalli D, Dieci MV. Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?[J]. Cancers (Basel), 2021, 13(7): 1655. doi: 10.3390/cancers13071655
|
| [25] |
陆娟, 冯晨露, 赵旭林. 人表皮生长因子受体2阳性乳腺癌患者程序性死亡受体配体1和免疫组化标志物表达与新辅助化疗疗效的关系[J]. 癌症进展, 2020, 18(20): 2087-2090, 2094. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202020010.htm
Lu J, Feng CL, Zhao XL. Relationship between expression of programmed cell death 1 ligand 1 and immunohistochemical markers and neoadjuvant chemotherapy efficacy in human epidermal growth factor receptor 2 positive breast cancer patients[J]. An Zheng Jin Zhan, 2020, 18(20): 2087-2090, 2094. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202020010.htm
|
| [26] |
黄世芬, 令晓玲. PD-1/PD-L1抑制剂联合抗血管生成药物治疗晚期三阴性乳腺癌的研究进展[J]. 肿瘤防治研究, 2021, 48(1): 75-81. doi: 10.3971/j.issn.1000-8578.2021.20.0615
Huang SF, Ling XL. Research Advances of PD-1/PD-L1 Inhibitors Combined with Angiogenesis Inhibitors in Treatment of Advanced Triple-negative Breast Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48(1): 75-81. doi: 10.3971/j.issn.1000-8578.2021.20.0615
|
| [27] |
Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(4): 499-511. doi: 10.1016/S1470-2045(20)30754-3
|
| [28] |
Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. doi: 10.1016/S0140-6736(20)32531-9
|
| [29] |
Schmid P, Cortés J, Dent R, et al. KEYNOTE-522: Phase Ⅲ study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)[J]. Ann Oncol, 2019, 30(Supl. 5): v853-v854.
|
| [30] |
Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study[J]. Ann Oncol, 2020, 31(5): 569-581. doi: 10.1016/j.annonc.2020.01.072
|
| [31] |
Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(3): 351-360. doi: 10.1016/S1470-2045(20)30702-6
|
| [32] |
Ma F, Li Q, Chen S, et al. Phase Ⅰ Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer[J]. J Clin Oncol, 2017, 35(27): 3105-3112. doi: 10.1200/JCO.2016.69.6179
|
| [33] |
陈怡萌, 徐兵河. HER2阳性乳腺癌酪氨酸激酶抑制剂治疗进展[J]. 临床肿瘤学杂志, 2021, 26(3): 265-271. doi: 10.3969/j.issn.1009-0460.2021.03.012
Chen YM, Xu BH. Progress of tyrosine kinase inhibitors in HER2 positive breast cancer[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2021, 26(3): 265-271. doi: 10.3969/j.issn.1009-0460.2021.03.012
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: